EPCAM and cancer: Evidence now supports that Bispecific T cell engagers (BiTEs) are highly effective in targeting CEA with MT111 for colorectal, ovary, and stomach cancer [1], CD19 for acute lymphatic leukemia (Blinatumomab) [2] and EpCAM for cancer related ascites (Catumaxomab).